Back to User profile » Dr Kieran J Rothnie

Papers published by Dr Kieran J Rothnie:


Benefit of Prompt Vs Delayed Initiation of Triple Therapy Following an Exacerbation in Patients with COPD in Japan: A Retrospective Cohort Study

Czira A, Akiyama S, Ishii T, Wood RP, Camidge LJ, Wallis H, Jennison T, Wild RAC, Yarita M, Hashimoto K, Rothnie KJ, Ismaila AS

International Journal of Chronic Obstructive Pulmonary Disease 2023, 18:2933-2953

Published Date: 8 December 2023

Risk Factors Associated with a First Exacerbation Among Patients with COPD Classified as GOLD A and B in Routine Clinical Practice in the UK

Rothnie KJ, Numbere B, Gelwicks S, Lu Y, Sharma R, Compton C, Ismaila AS, Quint JK

International Journal of Chronic Obstructive Pulmonary Disease 2023, 18:2673-2685

Published Date: 21 November 2023

Comparative Effectiveness of Umeclidinium/Vilanterol versus Indacaterol/Glycopyrronium on Moderate-to-Severe Exacerbations in Patients with Chronic Obstructive Pulmonary Disease in Clinical Practice in England

Requena G, Czira A, Banks V, Wood R, Tritton T, Castillo C, Yeap J, Wild R, Compton C, Rothnie KJ, Herth FJ, Quint JK, Ismaila AS

International Journal of Chronic Obstructive Pulmonary Disease 2023, 18:2039-2054

Published Date: 15 September 2023

Comparison of Rescue Medication Prescriptions in Patients with Chronic Obstructive Pulmonary Disease Receiving Umeclidinium/Vilanterol versus Tiotropium Bromide/Olodaterol in Routine Clinical Practice in England

Requena G, Czira A, Banks V, Wood R, Tritton T, Castillo CM, Yeap J, Wild R, Compton C, Rothnie KJ, Herth F, Quint JK, Ismaila AS

International Journal of Chronic Obstructive Pulmonary Disease 2023, 18:1431-1444

Published Date: 13 July 2023

Comparative Effectiveness of Umeclidinium/Vilanterol versus Inhaled Corticosteroid/Long-Acting β2-Agonist in Patients with Chronic Obstructive Pulmonary Disease in a Primary Care Setting in England

Czira A, Requena G, Banks V, Wood R, Tritton T, Castillo CM, Yeap J, Wild R, Compton C, Rothnie KJ, Herth F, Quint JK, Ismaila AS

International Journal of Chronic Obstructive Pulmonary Disease 2023, 18:643-659

Published Date: 19 April 2023

Comparative Adherence and Persistence of Single- and Multiple-Inhaler Triple Therapies Among Patients with Chronic Obstructive Pulmonary Disease in an English Real-World Primary Care Setting

Halpin DM, Rothnie KJ, Banks V, Czira A, Compton C, Wood R, Tritton T, Massey O, Wild R, Snowise N, Nikitin K, Sharma R, Ismaila AS, Vogelmeier CF

International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:2417-2429

Published Date: 24 September 2022

Characteristics of New Users of Single- and Multiple-Inhaler Triple Therapy for COPD in Primary Care in England

Rothnie KJ, Joksaite S, Sansbury LB, Compton C, Di Boscio V, Ismaila AS

International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:1455-1466

Published Date: 22 June 2022

Disease Burden and Healthcare Utilization Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in England

Sansbury LB, Lipson DA, Bains C, Anley GA, Rothnie KJ, Ismaila AS

International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:415-426

Published Date: 3 March 2022

Healthcare, Medication Utilization and Outcomes of Patients with COPD by GOLD Classification in England

Sansbury LB, Rothnie KJ, Bains C, Compton C, Anley G, Ismaila AS

International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:2591-2604

Published Date: 15 September 2021

Development and Validation of a Healthcare Utilization-Based Algorithm to Identify Acute Exacerbations of Chronic Obstructive Pulmonary Disease

Mapel DW, Roberts MH, Sama S, Bobbili PJ, Cheng WY, Duh MS, Nguyen C, Thompson-Leduc P, Van Dyke MK, Rothnie KJ, Sundaresan D, Certa JM, Whiting TS, Brown JL, Roblin DW

International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:1687-1698

Published Date: 9 June 2021